CLINICAL_TRIALS ClinicalTrials.gov record update

Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04603872
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:58.527132+00:00
Published At: 2020-10-28T00:00:00+00:00
Record Updated At: 2020-10-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory", "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphocytic Leukaemia Refractory", "Non-Hodgkin\u0027s Lymphoma, Relapsed", "Non-Hodgkin\u0027s Lymphoma Refractory"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-10-28"
protocolSection.identificationModule.nctId: "NCT04603872"
protocolSection.identificationModule.officialTitle: "Clinical Trial for the Safety and Efficacy of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin\u0027s Lymphoma and Multiple Myeloma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.